Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer

[1]  D. Révész,et al.  Decision support systems for incurable non-small cell lung cancer: a systematic review , 2017, BMC Medical Informatics and Decision Making.

[2]  P. Lambin,et al.  Decision support systems for personalized and participative radiation oncology☆ , 2017, Advanced drug delivery reviews.

[3]  W. Tam,et al.  Novel therapeutic targets on the horizon for lung cancer. , 2016, The Lancet. Oncology.

[4]  Y. Boumber,et al.  Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC , 2016, Front. Oncol..

[5]  Daniel L. Rubin,et al.  Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data , 2016, J. Biomed. Informatics.

[6]  D. Costa,et al.  Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches , 2016, Therapeutic advances in respiratory disease.

[7]  D. Ettinger,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Funda Meric-Bernstam,et al.  The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. , 2015, Drug discovery today.

[9]  Paul K J Han,et al.  Physicians' perceptions of the value of prognostic models: the benefits and risks of prognostic confidence , 2015, Health expectations : an international journal of public participation in health care and health policy.

[10]  N. Zhang,et al.  Incorporation of life expectancy estimates in the treatment of palliative care patients receiving radiotherapy: treatment approaches in light of incomplete prognostic models. , 2015, Annals of palliative medicine.

[11]  R. Gentzler,et al.  Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). , 2015, Translational lung cancer research.

[12]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Lei Han,et al.  Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis , 2015, Cancer biology & medicine.

[14]  P. Hammerman,et al.  Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics , 2015, Clinical Cancer Research.

[15]  E. Smets,et al.  Breast cancer specialists' views on and use of risk prediction models in clinical practice: A mixed methods approach , 2014, Acta oncologica.

[16]  E. Chow,et al.  How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. , 2013, International journal of radiation oncology, biology, physics.

[17]  Jae Park,et al.  How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey , 2013, BMC Medical Informatics and Decision Making.

[18]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Schiller,et al.  Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Jerome A. Osheroff,et al.  Bmc Medical Informatics and Decision Making Information Management to Enable Personalized Medicine: Stakeholder Roles in Building Clinical Decision Support , 2009 .

[21]  L. Seymour,et al.  A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  S. Ramalingam,et al.  Molecularly-targeted therapies for non-small cell lung cancer , 2005, Expert opinion on pharmacotherapy.

[23]  S. Rodenhuis,et al.  The molecular genetics of human lung cancer. , 1989, The European respiratory journal.

[24]  J. Gainor,et al.  Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. , 2017, The oncologist.

[25]  C. Rudin,et al.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.